Results 11 to 20 of about 5,279 (205)

REBOUND COVID-19 AFTER PAXLOVID IN 2 RELATED FAMILY MEMBERS [PDF]

International Journal of Infectious Diseases, 2023
Intro: On May 24, 2022, the CDC issued a healthcare advisory after reports of COVID-19 symptoms returning (COVID-19 rebound) in certain patients two to eight days after treatment with Paxlovid (Ritonavir-Boosted Nirmatrevir). We describe two patients who
P. Periyasamy, T. Li Fen, N. Kori, U.A. Zainulabid   +3 more
doaj   +2 more sources

A cost-effectiveness analysis of Molnupiravir and Paxlovid for outpatient treatment of COVID-19 in three African countries [PDF]

Journal of Public Health in Africa
Background: Two COVID-19 oral antivirals (COAVs), Molnupiravir and Paxlovid, have been shown to be cost-effective in high-income countries. Aim: This study assesses the cost-effectiveness of Paxlovid and Molnupiravir, compared to usual care in three ...
Ijeoma P. Edoka, Tom Drake, Peter Baker, Raji Tajudeen, Elias Asfaw, Javier Guzman, Nicaise Ndembi, Justice Nonvignon, Jean Kaseya   +8 more
doaj   +2 more sources

Computational molecular modeling of Paxlovid binding [PDF]

, 2022
Computational binding modeling of the drug Paxlovid to the 3CL-protease of SARS-Cov-2 is presented. Paxlovid contains 2 molecule ingredients: Nirmatrelvir and Ritonavir. This is a detailed distributional analysis using docking of both small molecules, to the target protease and to the CYP 3A4 liver enzyme.
Gordon, Chalmers
openaire   +2 more sources

Paxlovid plus glucocorticoids treatment in severe Omicron infected patients with hypoxaemia: A prospective multiple-center cohort study. [PDF]

PLoS ONE
BackgroundAdministration of Paxlovid in early stage has been proved to reduce the risk of hospitalization or death by 89% in mild to moderate COVID-19 patients with high-risk. There were few evidences of Paxlovid in severe COVID-19 patients.
Yu-Ji Wang, Nan Su, Jun-Hong Jiang, Guo-Peng Xu, Ran Wang, Da-Xiong Zeng, Jiao Zhu   +6 more
doaj   +2 more sources

Effect of Paxlovid treatment during acute COVID-19 on Long COVID onset: An EHR-based target trial emulation from the N3C and RECOVER consortia. [PDF]

PLoS Medicine
BackgroundPreventing and treating post-acute sequelae of COVID-19 infection (PASC), commonly known as Long COVID, has become a public health priority. This study tests whether Paxlovid treatment in the acute phase of COVID-19 could help prevent the onset
Alexander Preiss, Abhishek Bhatia, Leyna V Aragon, John M Baratta, Monika Baskaran, Frank Blancero, Michael Daniel Brannock, Robert F Chew, Iván Díaz, Megan Fitzgerald, Elizabeth P Kelly, Andrea G Zhou, Thomas W Carton, Christopher G Chute, Melissa Haendel, Richard Moffitt, Emily Pfaff, N3C Consortium and the RECOVER Cohort   +17 more
doaj   +2 more sources

Paxlovid reduces the 28-day mortality of patients with COVID-19: a retrospective cohort study

BMC Infectious Diseases
Purpose In this study, we aim to explore the efficacy of paxlovid on reducing mortality of COVID-19 patients in clinical setting, especially whether paxlovid modifies the risk of death in these severe and critical patients.
Kaican Zong, Li Xu, Chun Luo, Chen Luo, Bin Liu, Jiacheng Chen, Huizi Wu, Zhiqiang Liu, Rongjuan Zhuang, Shuliang Guo   +9 more
doaj   +2 more sources

A case report of severe hyponatremia secondary to Paxlovid‐induced SIADH

Clinical Case Reports, 2023
Key Clinical Message Nirmatrelvir‐ritonavir (Paxlovid) is a brand‐new oral antiviral medication for treating mild to severe COVID‐19. The Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for ritonavir‐nirmatrelvir on ...
Sarah Mohamed, Mostafa Reda Mostafa, Mohamed Magdi Eid, Yossef Hassan AbdelQadir, Yomna Ali Abdelghafar, Sarya Swed, Bishara Jahshan, Waddah Abd El‐Radi   +7 more
doaj   +2 more sources

Efficacy and safety of azvudine versus nirmatrelvir/ritonavir in cancer patients with COVID-19 [PDF]

Scientific Reports
Cancer significantly contributes to the unfavorable prognosis of coronavirus disease 2019 (COVID-19) patients. The efficacy and safety of azvudine and nirmatrelvir/ritonavir (Paxlovid) in cancer patients with COVID-19 remain uncertain.
Bohan Jia, Junyi Sun, Di Zhu, Ling Wang, Xiaobo Hu, Haiyu Wang, Guowu Qian, Donghua Zhang, Silin Li, Hong Luo, Shixi Zhang, Guotao Li, Guangming Li, Hongxia Liang, Zujiang Yu, Zhigang Ren   +15 more
doaj   +2 more sources

Real-world effectiveness and safety of oral azvudine versus Paxlovid in patients with COVID-19 and pre-existing hypertension: a multicentre, retrospective, cohort study in Henan Province, China [PDF]

BMJ Open
Objectives Azvudine and Paxlovid are the primary antiviral agents for the management of COVID-19. However, there is currently insufficient evidence regarding the effectiveness and safety of these drugs in treating COVID-19 patients with pre-existing ...
Ling Wang, Zhigang Ren, Xiaoli Jin, Hong Luo, Donghua Zhang, Ming Cheng, Fuwei Wang, Bohan Jia, Guotao Li, Mengzhao Yang, Guangming Li, Shixi Zhang, Guowu Qian, Silin Li, Hongxia Liang   +14 more
doaj   +2 more sources

Paxlovid utilization and social vulnerability: trends in Connecticut from 2022 to 2023 [PDF]

Antimicrobial Stewardship & Healthcare Epidemiology
The COVID-19 pandemic disproportionately affected vulnerable communities. Social vulnerability index (SVI) for census tracts with a Paxlovid dispensing site was higher than those without a dispensing site (0.56 vs. 0.45, P < .01).
Laura Hohenstein, Meghan Maloney, David B. Banach   +2 more
doaj   +2 more sources